BioSpace News Archive

One of the South West’s biggest technology companies, Falmouth-based Watson-Marlow Fluid Technology Group (WMFTG) – part of Spirax-Sarco Engineering plc – will celebrate International Women in Engineering Day (INWED) in partnership with Goonhilly Earth Station.

Codexis, Inc. (Nasdaq: CDXS), a leading synthetic biology company, announces that Casdin Capital, LLC, a New York City-based life science-focused investment firm and current stockholder of Codexis, has invested approximately $50 million in Codexis through the purchase of shares of Codexis’ common stock in a private placement.

Avacta Group plc (AIM: AVCT), the developer of Affimer®biotherapeutics and research reagents, and Selexis, a pioneering life sciences company and global leader in mammalian cell line generation technology, have partnered to develop the Chinese hamster ovary (CHO) cell line that will be used to manufacture Avacta’s first Affimer clinical candidate for first-time-in-human clinical trials

The sell-out UK Manufacturing Medicines Industry Partnership (MMIP) Annual Conference is taking place at Discovery Park today.

DIXI Holding Le Locle SA and Aleva Neurotherapeutics SA have co-founded Adept Neuro SA, a Joint Venture dedicated to developing a new generation of Stereo-Electro-Encephalo-Graphie (SEEG) electrodes which will facilitate localization and thermocoagulation of epileptogenic zones.

Bedfont Scientific Ltd., a Kent-based medical device manufacturer, has signed two esteemed respiratory professionals onto its Medical Advisory Board for its NObreath FeNO device.

Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today announced that it will present on its pipeline and strategy for the Company’s new classes of antibiotics at the American Society for Microbiology Microbe conference taking place 20-24 June 2019 in San Francisco, CA.

Microbiotica, a leading player in microbiome-based therapeutics, is pleased to confirm upcoming conference attendance and during summer 2019.

Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO).

Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, has announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share.